Oryzon Genomics S.A. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported sales was EUR 15.7 million compared to EUR 10.62 million a year ago. Net loss was EUR 4.23 million compared to EUR 4.69 million a year ago.
Market Closed -
Other stock markets
|
Pre-market 11:02:01 am | |||
1.88 EUR | -0.53% |
|
1.89 | +0.53% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-0.42% | 116M | |
+38.36% | 52.73B | |
+36.73% | 39B | |
-8.63% | 38.52B | |
+25.46% | 30.38B | |
-11.17% | 26.39B | |
+11.44% | 26.08B | |
+45.09% | 14.15B | |
+32.93% | 12.6B | |
-5.30% | 11.51B |
- Stock Market
- Equities
- ORY Stock
- News Oryzon Genomics S.A.
- Oryzon Genomics S.A. Reports Earnings Results for the Full Year Ended December 31, 2022